ArticleCancer cell2015
RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.
5 registry-linked trialsAbstract read
In one paragraph
Article in Cancer cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 522 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
522citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Platelet RNA Profiling to Detect Occult Cancer in Patients With Unprovoked Venous Thromboembolism
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN. REBORN Study
A Blinded Prospective Study on Development and Validation of the Blood Cell RNA-Based Cancer Detection
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier
Who cites it
522 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- [Liquid Biopsy Revolutionizes the Precise Management of Tumors Across the Entire Course: Current Situation and Future Prospects].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Pooled it
- New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.Briefings in bioinformatics · 2024Pooled it
- Identification of platelet-derived biomarker in a cohort of Parkinson's disease.Genes & diseases · 2027Article
- The molecular mechanisms of platelets in tumor invasion and metastasis: a controversial role.Cancer biology & therapy · 2026Review
- Niches in cancer: from primary tumors to metastatic disease.Journal of hematology & oncology · 2026Review
- Pulmonary nodules: classification, biomarkers, signaling pathways, diseases, early diagnosis and management.Signal transduction and targeted therapy · 2026Review
- Deepening the Understanding of Platelet-Derived RNA as Biomarker for Glioblastoma Through GSEA, TDEA, and Elastic Net Regularization Analysis.Cancer reports (Hoboken, N.J.) · 2026Article
- Towards liquid biopsy-based analysis of antitumour immunity.Nature reviews. Clinical oncology · 2026Review
- Development and validation of a serum peptidomic signature for early detection of asymptomatic ovarian cancer: A multi-center prospective study.Cell reports. Medicine · 2026Article
- Beyond the Needle: Is Liquid Biopsy the Future of Veterinary Medicine?International journal of molecular sciences · 2026Review
- Advancing the applications of liquid biopsies in oncology.Nature reviews. Genetics · 2026Review
- Platelet-derived mitochondrial transfer in cancer metastasis: mechanisms, functional consequences, and translational opportunities.Clinical & experimental metastasis · 2026Review
- Article
- Circulating Tumor DNA for Minimal Residual Disease Detection and Recurrence Prediction in Upper Gastrointestinal Cancers: A Scoping Review.Journal of clinical medicine · 2026Review
- Cancer of unknown primary: the evolution of tissue of origin identification in the artificial intelligence era.Biomarker research · 2026Review
- Platelets as regulators of cancer immunity: mechanisms and therapeutic perspectives.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Tumour-Derived Extracellular Vesicles Containing dsRNA Induce Degradation of Ribosomal Protein mRNA in Platelets.Journal of extracellular vesicles · 2026Article
- Tumor-platelet cross talk in cancer: mechanisms, thrombotic risk, and translational opportunities.Blood advances · 2026Review
- Review
- Article
462 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
21 authors.
Myron G BestDepartment of Pathology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Nik SolDepartment of Neurology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Irsan KooiDepartment of Clinical Genetics, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Jihane TannousDepartment of Neurology, Massachusetts General Hospital and Neuroscience Program, Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.
Bart A WestermanDepartment of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
François RustenburgDepartment of Pathology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Pepijn SchellenDepartment of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; thromboDx B.V., 1098 EA Amsterdam, the Netherlands.
Heleen VerschuerenDepartment of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; thromboDx B.V., 1098 EA Amsterdam, the Netherlands.
Edward PostDepartment of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; thromboDx B.V., 1098 EA Amsterdam, the Netherlands.
Jan KosterDepartment of Oncogenomics, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
Bauke YlstraDepartment of Pathology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Najim AmezianeDepartment of Clinical Genetics, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Josephine DorsmanDepartment of Clinical Genetics, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Egbert F SmitDepartment of Pulmonary Diseases, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Henk M VerheulDepartment of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
David P NoskeDepartment of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Jaap C ReijneveldDepartment of Neurology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
R Jonas A NilssonDepartment of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; thromboDx B.V., 1098 EA Amsterdam, the Netherlands; Department of Radiation Sciences, Oncology, Umeå University, 90185 Umeå, Sweden.
Bakhos A TannousDepartment of Neurology, Massachusetts General Hospital and Neuroscience Program, Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.
Pieter WesselingDepartment of Pathology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of Pathology, Radboud University Medical Center, 6500 HB Nijmegen, the Netherlands.
Thomas WurdingerDepartment of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of Neurology, Massachusetts General Hospital and Neuroscience Program, Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA; thromboDx B.V., 1098 EA Amsterdam, the Netherlands. Electronic address: t.wurdinger@vumc.nl.
Funding
The role of microvesicles in giloma virotherapyP01CA069246 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAREST, ALAIN · 1996 to 2021
$30.9MDetection of NSCLC-derived mutant RNA in plateletsR21CA176359 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI TANNOUS, BAKHOS A · 2013 to 2014
$391kNCI NIH HHS CA069246NCI NIH HHS NIH/NCI CA176359NCI NIH HHS P01 CA069246NCI NIH HHS R21 CA176359
Abstract
Tumor-educated blood platelets (TEPs) are implicated as central players in the systemic and local responses to tumor growth, thereby altering their RNA profile. We determined the diagnostic potential of TEPs by mRNA sequencing of 283 platelet samples. We distinguished 228 patients with localized and metastasized tumors from 55 healthy individuals with 96% accuracy. Across six different tumor types, the location of the primary tumor was correctly identified with 71% accuracy. Also, MET or HER2-positive, and mutant KRAS, EGFR, or PIK3CA tumors were accurately distinguished using surrogate TEP mRNA profiles. Our results indicate that blood platelets provide a valuable platform for pan-cancer, multiclass cancer, and companion diagnostics, possibly enabling clinical advances in blood-based "liquid biopsies".
Indexed as
AdultAgedAged, 80 and overBiomarkers, TumorBlood PlateletsClass I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesErbB ReceptorsFemaleGene Expression ProfilingGene OntologyHumansMaleMiddle AgedMutationNeoplasmsBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesEGFR protein, humanErb-b2 Receptor Tyrosine KinasesErbB ReceptorsKRAS protein, humanMET protein, humanPhosphatidylinositol 3-KinasesPIK3CA protein, humanProto-Oncogene Proteins c-metProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT02739867ClinicalTrials.gov
NCT04464122ClinicalTrials.gov
NCT05839834ClinicalTrials.gov
NCT06717295ClinicalTrials.gov
NCT07460440ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.